Artiva Biotherapeutics

Company snapshot

Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the ac

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Artiva Biotherapeutics. Not investment advice.

• Peer + 0 momentum

  HOFFMANN-LA ROCHE

  TA overlap score 40

• Peer + 0 momentum

  Universal Integrated

  TA overlap score 37.8

Recent activity

Latest pipeline, patent, and corporate events for Artiva Biotherapeutics.

1. Jun 8, 2026 Clinical update

   AB-101-05 — Phase 2

2. Jun 8, 2026 Clinical update

   Allogeneic NK Cells — Phase 2

3. Jun 5, 2026 Clinical update

   GCC2005 — Phase 1

4. Jun 5, 2026 Clinical update

   AFM13 — Phase 2

5. May 23, 2026 Clinical update

   AB-101 — Phase 2

View all clinical trial activity →

• What is Artiva Biotherapeutics?

  Artiva Biotherapeutics is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker ARTV. Primary therapeutic focus areas include Lupus Nephritis - WHO Class III, Non Hodgkin Lymphoma, Rheumatoid Arthritis, Breast Cancer, Relapsed or Refractory Hodgki

• Is Artiva Biotherapeutics publicly traded?

  Yes. Artiva Biotherapeutics is listed with ticker ARTV on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Artiva Biotherapeutics develop or market?

  We link 9 drug profile(s) where Artiva Biotherapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/artiva-biotherapeutics#company-drugs.

• What are the latest developments for Artiva Biotherapeutics?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Artiva Biotherapeutics focus on?

  Artiva Biotherapeutics focuses on Lupus Nephritis - WHO Class III, Non Hodgkin Lymphoma, Rheumatoid Arthritis based on our analysis of their pipeline programs and drug development activities.